XSHE
002004
Market cap1.29bUSD
Oct 09, Last price
4.57CNY
1D
5.06%
1Q
10.65%
Jan 2017
-49.61%
IPO
293.97%
Name
Huapont Life Sciences Co Ltd
Chart & performance
P/E
12.69
P/S
0.79
EPS
0.36
Div yield, %
4.60%
Shrs. gr., 5y
-0.07%
Rev. gr., 5y
-1.52%
Revenues
11.51b
-1.31%
Net income
713m
P
CFO
2.10b
+28.96%
Dividend
Sep 23, 20260.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Huapont Life Sciences Co., Ltd. is a multifaceted company engaged in both the pharmaceutical and agrochemical industries, with operations spanning China and international markets. Its pharmaceutical arm is dedicated to the manufacture and distribution of medicinal preparations and their precursors. The company offers a broad range of healthcare products, including treatments for skin conditions, tuberculosis, infections, respiratory issues, cancer, and eye ailments, in addition to general wellness products. Within its agrochemical division, Huapont supplies technical pesticides, intermediates, and finished products, alongside providing technical services for GLP registration. Founded in 2001 and based in Chongqing, China, the company adopted its current name, Huapont Life Sciences Co., Ltd., in September 2015, having previously been known as Huapont-Nutrichem Co., Ltd. It was formerly a subsidiary of Huipont Tourism Co. Ltd.
Key people
Rong Wang
Vice Chairman of the Board · since 2025
Chief Financial Officer · since 2014
General Manager, Director · since 2018
Jingjing Hu
Secretary of the Board · since 2025
Yunhui Peng
Secretary of the Board, Director · since 2007
Xi Wang
Staff Elected Director · since 2025
Songshan Zhang
Chairman of the Board · since 2018
Ming Li
Independent Director · since 2021
Independent Director · since 2021
Headquarters & legal address
重庆市渝北区人和星光大道69号
渝北区, CQ 100000
CN
渝北区, CQ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2021‑00 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||||
Revenues | ||||||||||||||
Cost of revenue | ||||||||||||||
Unusual Expense (Income) | ||||||||||||||
NOPBT | ||||||||||||||
NOPBT Margin | ||||||||||||||
Operating Taxes | ||||||||||||||
Tax Rate | ||||||||||||||
NOPAT | ||||||||||||||
Net income | ||||||||||||||
Dividends | ||||||||||||||
Dividend yield | ||||||||||||||
Proceeds from repurchase of equity | ||||||||||||||
BB yield | ||||||||||||||
| Debt | ||||||||||||||
Debt current | ||||||||||||||
Long-term debt | ||||||||||||||
Deferred revenue | ||||||||||||||
Other long-term liabilities | ||||||||||||||
Net debt | ||||||||||||||
| Cash flow | ||||||||||||||
Cash from operating activities | ||||||||||||||
CAPEX | ||||||||||||||
Cash from investing activities | ||||||||||||||
Cash from financing activities | ||||||||||||||
FCF | ||||||||||||||
| Balance | ||||||||||||||
Cash | ||||||||||||||
Long term investments | ||||||||||||||
Excess cash | ||||||||||||||
Stockholders' equity | ||||||||||||||
Invested Capital | ||||||||||||||
ROIC | ||||||||||||||
ROCE | ||||||||||||||
| EV | ||||||||||||||
Common stock shares outstanding | ||||||||||||||
Price | ||||||||||||||
Market cap | ||||||||||||||
EV | ||||||||||||||
EBITDA | ||||||||||||||
EV/EBITDA | ||||||||||||||
Interest | ||||||||||||||
Interest/NOPBT | ||||||||||||||